These dual targeting could allow to significantly reduce toxicity: the drug is delivered to the tumor site, which reduce systemic toxicity, and then the targeting of mitochondria could allow a specific inhibition of TRAP1. The gene discussed is TRAP1; the disease is neoplasm.